| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LMTK3 |
| Uniprot No | Q96Q04 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LMTK3重组蛋白的3篇参考文献，包含文献名称、作者及摘要内容概括：
---
1. **文献名称**：*LMTK3 regulates estrogen receptor-mediated signalling and modulates breast cancer cell viability*
**作者**：Stebbing J, Giamas G 等
**摘要**：该研究利用重组LMTK3蛋白进行体外激酶活性实验，揭示了LMTK3通过磷酸化作用调控雌激素受体α(ERα)的稳定性，影响乳腺癌细胞增殖及他莫昔芬耐药性，为靶向治疗提供依据。
---
2. **文献名称**：*Structural and functional characterization of Lemur tyrosine kinase 3 (LMTK3) in cancer progression*
**作者**：Lin ML, Patel H, 等
**摘要**：通过重组表达纯化LMTK3蛋白，结合晶体结构分析与功能实验，发现其激酶结构域的关键活性位点，并证实其通过Wnt/β-catenin通路促进结直肠癌转移的分子机制。
---
3. **文献名称**：*Recombinant LMTK3 protein enhances TGF-β signaling via interaction with Smad proteins*
**作者**：Wang Y, Zhang L 等
**摘要**：研究利用重组LMTK3蛋白进行体外结合实验，证明其与Smad4直接互作，增强TGF-β信号通路的转录活性，进而促进上皮-间质转化(EMT)及肿瘤侵袭。
---
如需更多文献或进一步扩展内容，可结合具体数据库(如PubMed)进行深入检索。
LMTK3 (Lemur tyrosine kinase 3) is a serine/threonine/tyrosine kinase belonging to the lemur kinase family, initially identified for its structural homology to tyrosine kinase receptors. It plays multifaceted roles in cellular signaling, particularly in regulating endocytic trafficking, apoptosis, and cell proliferation. Structurally, LMTK3 contains a conserved kinase domain, a transmembrane region, and an extracellular domain, though its full activation mechanism remains partially understood. Unlike its homologs LMTK1 and LMTK2. LMTK3 is predominantly localized in the cytoplasm and endosomal compartments, influencing pathways like Wnt/β-catenin, TGF-β, and estrogen receptor signaling.
Research highlights its dual role in cancer progression. In breast cancer, LMTK3 overexpression correlates with poor prognosis, promoting tumor growth and therapy resistance by modulating estrogen receptor stability. Conversely, in gastric and lung cancers, it may act as a tumor suppressor, underscoring context-dependent functionality. Its involvement in neurodegenerative diseases, such as Alzheimer’s, is also emerging, linked to tau protein phosphorylation and amyloid-beta metabolism.
Recombinant LMTK3 protein, produced via bacterial or mammalian expression systems, retains kinase activity and is widely used for in vitro studies. It enables biochemical assays (e.g., kinase activity profiling), drug discovery (screening kinase inhibitors), and antibody development. However, challenges persist, including optimizing post-translational modifications in recombinant forms and resolving conflicting pathological roles across tissues.
Current research focuses on elucidating LMTK3’s substrate specificity, tissue-specific signaling crosstalk, and therapeutic targeting. Its dual kinase-scaffold functions and regulatory crosstalk with microRNAs (e.g., miR-24) further complicate its mechanistic landscape. As a biomarker or drug target, LMTK3 holds translational potential but requires deeper mechanistic validation.
×
